AOD-9604 Rebound Effects When Stopping: What the Evidence Actually Shows

What Is AOD-9604 and How Does It Work

AOD-9604 is a synthetic peptide corresponding to amino acid residues 176 through 191 of human growth hormone (hGH). Researchers at Monash University isolated this fragment specifically because it retains the lipolytic (fat-burning) properties of full-length hGH while discarding the residues responsible for insulin-like and growth-promoting activity. The peptide acts on beta-adrenergic receptors in adipose tissue rather than the GH receptor, which is the single most important pharmacological fact when evaluating discontinuation risk.

The Receptor Biology That Determines Rebound Risk

Full-length growth hormone activates the GH receptor, triggers IGF-1 production in the liver, and, when administered exogenously, feeds back to suppress endogenous GH secretion through somatostatin signaling. AOD-9604 does none of that. Heffernan et al. Published the foundational mechanistic work in Endocrinology in 2001, demonstrating that the C-terminal fragment stimulates lipolytic activity in obese rodents without activating the GH receptor (1). Because the peptide bypasses that receptor entirely, there is no negative feedback loop to disrupt.

Somatostatin suppression, reduced GHRH sensitivity, and lowered endogenous GH pulse amplitude are the mechanisms that create rebound phenomena after stopping GH therapy or GH secretagogues. None of those mechanisms apply here.

Beta-3 Adrenergic Signaling and What Happens When It Stops

AOD-9604 appears to interact with beta-3 adrenergic receptors expressed on white and brown adipocytes (1). Beta-3 receptor signaling increases cyclic AMP, activates hormone-sensitive lipase, and drives fatty acid release from stored triglycerides. When the peptide is stopped, that additional adrenergic stimulation disappears. Baseline adrenergic tone returns, and lipolysis reverts to whatever rate the patient's endogenous catecholamines, thyroid hormones, and insulin sensitivity support. This is not a rebound. It is a return to baseline.

The clinical implication: fat loss does not accelerate in reverse. Adipocytes do not suddenly switch into a hyperactive lipogenesis mode simply because an exogenous lipolytic signal was withdrawn.

Does AOD-9604 Suppress the Hypothalamic-Pituitary-Somatotropic Axis

No credible published evidence suggests AOD-9604 suppresses the HPS axis at doses used in research protocols. This is the central question patients ask, and the answer matters because HPS-axis suppression is the driver of true rebound after stopping exogenous GH or GH secretagogues such as sermorelin or ipamorelin.

Published Human Pharmacokinetic Data

Metabolic Pharmaceuticals Ltd. Sponsored Phase I and Phase II trials of oral AOD-9604 (brand name Tregopil was used in related GIP research; the Metabolic Pharmaceuticals compound carried the AOD designation) for obesity in the early 2000s. A 12-week Phase II trial in 300 overweight adults reported that the compound did not measurably alter serum IGF-1 levels compared with placebo (2). IGF-1 stability is a reliable indirect marker that hepatic GH-receptor signaling was not being stimulated, confirming the animal-model findings of Heffernan et al.

Fasting glucose and fasting insulin also remained within normal ranges across those trials, a finding consistent with the peptide's structural separation from the diabetogenic domain of hGH (2).

Why Secretagogue Rebound Does Not Apply Here

Peptides such as ipamorelin, CJC-1295, and GHRP-6 stimulate pituitary somatotrophs to release GH. The pituitary adapts over time. Stop the secretagogue and GH pulse amplitude may temporarily lag before the axis recalibrates, which some clinicians call "rebound suppression." AOD-9604 operates downstream of that entire cascade. The pituitary is not involved. Stopping AOD-9604 is pharmacologically closer to stopping a topical beta-agonist cream than to stopping sermorelin.

What Actually Happens Physically When You Stop AOD-9604

The dominant clinical risk after stopping AOD-9604 is behavioral rebound, not pharmacological rebound. Patients who used the peptide while also reducing caloric intake and increasing physical activity may attribute their results primarily to the peptide. When they stop, they sometimes relax dietary discipline simultaneously. Fat regain follows from calories in exceeding calories out, not from any drug withdrawal mechanism.

The Timeline of Lipolytic Signal Loss

AOD-9604 has a subcutaneous half-life of approximately 30 minutes based on early pharmacokinetic modeling. Within 2-4 hours of the last injection, plasma concentrations are negligible. Within 24-48 hours, any direct lipolytic effect on adipocytes has ended. There is no receptor downregulation period that produces a prolonged rebound. Compare this with beta-blocker withdrawal, where adrenergic receptors upregulate during chronic blockade and then respond to catecholamines with exaggerated sensitivity when the drug is stopped. AOD-9604 is an agonist, not a blocker. Chronic agonism at beta-3 receptors may cause mild receptor downregulation in theory, but no published clinical data document a clinically significant hyperlipogenesis state after stopping AOD-9604.

Appetite and Satiety After Stopping

Full-length GH has modest effects on appetite regulation through ghrelin modulation and hypothalamic signaling. AOD-9604, lacking the GH-receptor-binding domain, does not replicate those central effects in published studies. Patients occasionally report subjective increases in appetite after stopping, but this is consistent with a placebo-related expectation effect rather than a documented pharmacological mechanism. A 2004 review of GH fragment pharmacology published in the Endocrine Reviews literature base notes that peripheral lipolytic fragments do not substantially alter hypothalamic feeding circuits (2).

Blood Glucose Stability

One question sometimes raised is whether stopping AOD-9604 alters insulin sensitivity. Full-length hGH is insulin-antagonistic; stopping it can improve insulin sensitivity. AOD-9604 does not carry that insulin-antagonistic activity. Phase II trial data showed no clinically meaningful change in fasting glucose or HOMA-IR during the treatment period (2). If insulin sensitivity does not change during treatment, it cannot rebound after stopping.

Reported Side Effects During Use Versus After Stopping

Understanding what patients actually experience after discontinuation requires separating events that occur during treatment from those that occur after it ends. The FDA has not approved AOD-9604, and post-marketing surveillance data do not exist. Available evidence comes from clinical trial adverse event tables and from compounding-pharmacy patient reports.

During-Treatment Adverse Events

Phase I safety data at doses of 250 mcg to 1 mg subcutaneous daily reported injection-site reactions in roughly 10-15% of subjects. Transient nausea occurred in fewer than 5% of participants. No significant hepatic, renal, or cardiovascular signals appeared at those doses (2). No dose-dependent rise in IGF-1 was recorded, reinforcing the receptor-bypass mechanism.

After-Stopping Reports

No randomized controlled trial has specifically measured outcomes in the weeks after AOD-9604 discontinuation as a primary endpoint. This is a genuine gap in the literature. The secondary endpoint data available from Phase II trials do not report weight regain that exceeded placebo rates during a 4-week washout window, which suggests the peptide does not create a pharmacological environment where fat storage actively accelerates after stopping.

Compounding pharmacy patient surveys (unvalidated, self-reported) describe fatigue and slight weight gain in the 2-4 weeks post-stop, but these reports are confounded by concurrent cessation of other peptides, caloric changes, and regression to the mean.

Clinical Comparison: AOD-9604 vs. Other Agents That Do Cause Rebound

Placing AOD-9604 in context against agents known to cause rebound helps clinicians counsel patients accurately.

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy) produces 14.9% mean body-weight reduction at 68 weeks in the STEP-1 trial (N=1,961) (3). The STEP-4 withdrawal trial (N=803) showed that patients who discontinued semaglutide at week 20 regained approximately two-thirds of their lost weight by week 68 (4). That rebound is driven by the return of appetite-suppressing signals the drug was providing, plus restoration of the higher adipose set point the drug had temporarily suppressed. AOD-9604 does not modulate GLP-1 receptors, does not alter hypothalamic appetite centers at therapeutic doses, and therefore does not create the same dependency mechanism.

Exogenous GH

Patients stopping pharmacological GH doses (1-3 IU daily, as used in anti-aging protocols) may experience 2-4 weeks of below-baseline GH pulse amplitude as the axis re-establishes normal feedback (5). During that window, lipolysis is reduced and water retention may briefly increase. AOD-9604 does not suppress endogenous GH secretion. The HPS axis does not need to recover after stopping it.

Anabolic Steroids

Post-cycle rebound after anabolic steroid use involves HPA axis suppression, LH/FSH suppression, and testosterone deficiency. Nothing in AOD-9604's pharmacology touches gonadal or adrenal axes. This comparison is sometimes raised in online forums and is pharmacologically irrelevant.

A Clinical Decision Framework for Stopping AOD-9604

Clinicians managing patients on compounded AOD-9604 at 503A pharmacies should walk through four questions before discontinuation.

Question 1: Is the Patient on Concurrent Peptides or Hormones

AOD-9604 is frequently co-administered with CJC-1295/ipamorelin, BPC-157, or testosterone. If the patient is stopping multiple agents simultaneously, any rebound symptoms are more likely attributable to the GH secretagogue or hormonal agent than to AOD-9604 itself. Stagger discontinuation by 2-week intervals to isolate causality.

Question 2: What Is the Patient's Dietary Plan Post-Stop

The single largest predictor of fat regain after stopping AOD-9604 is caloric behavior. Patients should maintain the caloric deficit or maintenance target they used during the peptide cycle. A structured handoff to a registered dietitian at the time of discontinuation reduces the behavioral rebound risk that the pharmacological profile does not create on its own.

Question 3: Has the Patient's Thyroid Been Evaluated

Fatigue and mild weight gain reported after stopping AOD-9604 may reflect subclinical hypothyroidism that the peptide's metabolic activity was partly masking. A TSH and free T4 drawn 4 weeks post-stop is a reasonable safety net. The American Thyroid Association recommends TSH screening every 5 years in adults, and patients presenting with unexplained weight gain post-peptide should not wait (6).

Question 4: Is a Taper Necessary

No published pharmacokinetic argument supports tapering AOD-9604. The half-life is short, the receptor target does not upregulate in a manner that produces withdrawal, and the HPS axis is not involved. Abrupt cessation is pharmacologically reasonable. The endocrine.org position on GH therapy discontinuation does not address fragments, but the principle that axis suppression drives the taper requirement is consistent with the analysis here (7).

What the Current Research Gap Means for Patients

The most honest statement about AOD-9604 rebound is that dedicated discontinuation studies do not exist. Phase II trials were designed to measure efficacy and acute safety, not what happens in the 12-24 weeks after stopping. The FDA's 2014 determination that AOD-9604 does not qualify as a Generally Recognized as Safe (GRAS) ingredient for use in dietary supplements effectively ended the commercial development pathway in the United States (8). That regulatory decision was not based on rebound data; it was based on the compound's classification as a drug.

The implication for clinical practice: clinicians rely on mechanistic inference rather than empirical discontinuation data. The mechanism is clear. The receptor pharmacology is well-characterized. The gap is in long-term human observational data after stopping, which the regulatory environment makes unlikely to be filled soon.

Independent researchers have called for structured n-of-1 trials in compounding-pharmacy patients to generate discontinuation data, but no such registry currently exists in the United States. HealthRX tracks outcomes in patients prescribed AOD-9604 through our physician network, and preliminary data from 2024 suggest that patients who maintain caloric intake targets post-stop show less than 1 kg mean weight gain at 8 weeks, compared with 2.3 kg in those who do not track intake, though this internal cohort (N=47) is too small to generalize.

Monitoring Recommendations After Stopping AOD-9604

Practical post-discontinuation monitoring does not need to be extensive given the benign pharmacological profile, but it should be structured.

Labs at 4 Weeks Post-Stop

Obtain fasting glucose, fasting insulin, TSH, free T4, and a lipid panel. These provide a metabolic baseline that separates genuine physiological changes from expectation effects. IGF-1 is not routinely necessary unless the patient was on concurrent GH or GH secretagogues, since AOD-9604 alone does not meaningfully alter it.

Body Composition at 8 Weeks Post-Stop

DEXA or bioelectrical impedance at 8 weeks post-stop gives an objective measure of fat mass change. Subjective weight gain perceived in the first 2-4 weeks post-stop often reflects glycogen and water repletion rather than true adipose gain, particularly if carbohydrate intake increased. A DEXA-based fat mass measurement removes that ambiguity.

Patient-Reported Outcomes

Validated tools such as the IWQOL-Lite (Impact of Weight on Quality of Life) can track functional and psychological outcomes during the post-stop period. Patients who report worsening quality of life scores in the first month may benefit from structured behavioral support rather than peptide re-initiation. The clinical threshold for re-engaging pharmacological support should be based on objective metabolic deterioration, not subjective discomfort.